Blue Cross and Blue Shield of Minnesota has filed a class-action lawsuit — on behalf of itself and insurers from 30-plus states — against Martin Shkreli and Vyera Pharmaceuticals. The suit alleges the defendants intentionally monopolized the market for Daraprim to raise the price of the drug by more than 4,000%.
The drug, used to treat toxoplasmosis infection, became the subject of notoriety in 2015 when manufacturer Turing Pharmaceuticals, then led by Shkreli, raised the price from $13.50 to $750 per pill, making it a poster child for the issue of high drug prices.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In charges announced Monday, the agency says Vyera Pharmaceuticals - formerly Turing Pharma - used deals with distributors to prevent generic companies from obtaining samples and sales data for Daraprim. Vyera called the charges meritless.
Nevertheless, the proposed policy could take Martin Shkreli-like practices "out of the ballgame," expert says.
"In this particular case, the only thing I'd be impartial about is what prison he goes to," said a potential juror on day three of Martin Shkreli's high-profile court case, highlighting the challenge of jury selection.
Also, Chimerix reports another failed Phase 3 trial of brincidofovir, population health IT tools may become "irrelevant" and Republican healthcare policy wonks distance themselves from Trump.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The organization's all about generic drugs - but unlike, say, Martin Shkreli, Bloom's big idea is to repurpose existing drugs and lessen the overall costs of healthcare.
In the wake of its relationship with Martin Shkreli, KaloBios' new CEO Cameron Durrant "wants to clean up the messy legacy and start afresh," he said.
Also, a potentially game changing approach to kidney transplants and Alphabet is selling is robotics business.
During today’s congressional hearing on drug pricing, Rep. Jason Chaffetz (R-Utah) made his own case against the price gouging antics seen at Turing Pharmaceuticals. He pointed out a number of salary hikes seen last year among Turing’s top executives, as noted in documentation received by the House Oversight and Government Reform Committee in advance of the hearing. […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Congressmen were up in arms over Martin Shkreli's disrespectful behavior - and that fueled their attacks against drug pricing in the pharmaceutical industry. Here are four of their most interesting rants.
Martin Shkreli Shkreli talks about cocaine in a new video railing against Wu Tang Clan member Ghostface Killah. Perhaps he should be talking about clozapine instead.
Martin Shkreli won't violate the terms of his bail when he travels to Washington to appear before a congressional committee on drug pricing, the U.S. DOJ writes.
Martin Shkreli won't talk drug prices at his forthcoming Congressional hearing, because Turing Pharmaceuticals is under an FTC antitrust probe.
Along with Turing Pharmaceuticals, of which Martin Shkreli was formerly CEO, Valeant Pharmaceuticals will be investigated by Congress on January 26, Bloomberg reports.